Background: Accumulating evidence has shown that microRNAs (miRNAs) are aberrantly expressed in human esophageal cancer and crucial to tumorigenesis. Herein, we identified the role of miR-145 in esophageal squamous cell carcinoma (ESCC) development in vitro and in vivo. Material and Methods: miR-145 expression was investigated in 40 ESCC samples as well as 5 ESCC cell lines by real-time polymerase chain reaction. Crystal violet and transwell assays were conducted to explore the effects of miR-145 on the proliferation and invasion of human ESCC cell lines, respectively. The impact of overexpression of miR-145 on putative target c-Myc was subsequently confirmed via Western blot. Results: miR-145 expression was frequently downregulated in ESCC specimens and cell lines compared with adjacent normal tissues (p < 0.05). Overexpression of miR-145 suppressed (p < 0.05) ESCC cell proliferation and invasion, as well as the growth of xenograft tumors in mice. Overexpression of miR-145 significantly decreased (p < 0.05) the protein level of c-Myc which has previously been identified as a direct target of miR-145. Conclusion: Our results demonstrate that overexpression of miR-145 inhibits tumor growth in part by targeting c-Myc. Our findings revealed that miR-145 may act as a tumor suppressor in ESCC, and its dysregulation may be involved in the initiation and development of human ESCC.

Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000 the global picture. Eur J Cancer 2001;37:S4S66.
Wheeler JB, Reed CE: Epidemiology of esophageal cancer. Surg Clin North Am 2012;92:1077-87.
Xing D, Tan W, Lin D: Genetic polymorphisms and susceptibility to esophageal cancer among Chinese population. Oncol Rep 2003;10:1615-23.
No authors listed: Esophageal cancer: epidemiology, pathogenesis and prevention. Nat Clin Pract Gastroenterol 2008;5:517-26.
Thallinger CM, Kiesewetter B, Raderer M, Hejna M: Pre- and postoperative treatment modalities for esophageal squamous cell carcinoma. Anticancer Res 2012;32:4609-27.
Kranzfelder M, Büchler P, Friess H: Surgery within multimodal therapy concepts for esophageal squamous cell carcinoma (ESCC): the MRI approach and review of the literature. Adv Med Sci 2009;54:158-69.
Farazi TA, Hoell JI, Morozov P, Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol 2013;774:1-20.
Wang Z, Yao H, Lin S, Zhu X, Shen Z, Lu G, 16 Poon WS, Xie D, Lin MC, Kung HF: Transcriptional and epigenetic regulation of human microRNAs. Cancer Lett 2013;331:1-10.
Lages E, Ipas H, Guttin A, Nesr H, Berger F, Issartel JP: MicroRNAs: molecular features and role in cancer. Front Biosci 2012;17:2508-40.
Xing AY, Wang B, Shi DB, Zhang XF, Gao C, He XQ, Liu WJ, Gao P: Deregulated expression of miR-145 in manifold human cancer cells. Exp Mol Pathol 2013;95:91-7.
Wu BL, Xu LY, Du ZP, Liao LD, Zhang HF, Huang Q, Fang GQ, Li EM: MiRNA profile in esophageal squamous cell carcinoma: downregulation of miR-143 and miR-145. World J Gastroenterol 2011;17:79-88.
Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M, Matsubara H: miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010;127:2804-14.
Sato F, Tsuchiya S, Meltzer SJ, Shimizu K. MicroRNAs and epigenetics: FEBS J 2011;278:1598-609.
Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM, Zhang GZ: Biological functions of microRNAs: a review. J Physiol Biochem 2011;67:129-39.
Gao L, Ren W, Chang S, Guo B, Huang S, Li M, Guo Y, Li Z, Song T, Zhi K, Huang C: Downregulation of miR-145 expression in oral squamous cell carcinomas and its clinical significance. Onkologie 2013;36:194-9.
Noh JH, Chang YG, Kim MG, Jung KH, Kim JK, Bae HJ, Eun JW, Shen Q, Kim SJ, Kwon SH, Park WS, Lee JY, Nam SW: MiR-145 functions as a tumor suppressor by directly targeting histone deacetylase 2 in liver cancer. Cancer Lett 2013;335:455-62.
Slaby O, Svoboda M, Fabian P, Smerdova T, Knoflickova D, Bednarikova M, Nenutil R, Vyzula R: Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology 2007;72:397-402.
Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, Naya Y, Ichikawa T, Seki N: Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol 2011;38:1093-101.
Xu F, Wang H, Zhang X, Liu T, Liu Z: Cell proliferation and invasion ability of human choriocarcinoma cells lessened due to inhibition of Sox2 expression by microRNA-145. Exp Ther Med 2013;5:77-84.
Ritchie W, Rasko JE, Flamant S: MicroRNA target prediction and validation. Adv Exp Med Biol 2013;774:39-53.
Witkos TM, Koscianska E, Krzyzosiak WJ: Practical aspects of microRNA target prediction. Curr Mol Med 2011;11:93-109.
Li SQ, Wang HM, Cao XF: Potential clinical insights into microRNAs and their target genes in esophageal carcinoma. Biomarkers 2011;16:629-36.
Chen Z, Zeng H, Guo Y, Liu P, Pan H, Deng A, Hu J: miRNA-145 inhibits non-small cell lung cancer cell proliferation by targeting c-Myc. J Exp Clin Cancer Res 2010;29:151.
Sachdeva M, Mo YY: miR-145-mediated suppression of cell growth, invasion and metastasis. Am J Transl Res 2010;2:170-80.
Kim SJ, Oh JS, Shin JY, Lee KD, Sung KW, Nam SJ, Chun KH: Development of microRNA-145 for therapeutic application in breast cancer. J Control Release 2011;155:427-34.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.